Mechthild Jonas
Overview
Explore the profile of Mechthild Jonas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heiser R, Cao A, Zeng W, Ulrich M, Younan P, Anderson M, et al.
Mol Cancer Ther
. 2023 Sep;
23(1):68-83.
PMID: 37775098
Brentuximab vedotin, a CD30-directed antibody-drug conjugate (ADC), is approved for clinical use in multiple CD30-expressing lymphomas. The cytotoxic payload component of brentuximab vedotin is monomethyl auristatin E (MMAE), a highly...
2.
Lyon R, Jonas M, Frantz C, Trueblood E, Yumul R, Westendorf L, et al.
Mol Cancer Ther
. 2023 Aug;
22(12):1444-1453.
PMID: 37619980
Integrin beta-6, a component of the heterodimeric adhesion receptor alpha-v/beta-6, is overexpressed in numerous solid tumors. Its expression has been shown by multiple investigators to be a negative prognostic indicator...
3.
Meyer D, Bou L, Shum S, Jonas M, Anderson M, Hamilton J, et al.
Mol Pharm
. 2020 Jan;
17(3):802-809.
PMID: 31976667
While antibody-drug conjugates (ADCs) are advancing through clinical testing and receiving new marketing approvals, improvements to the technology continue to be developed in both academic and industrial laboratories. Among the...
4.
Li F, Sutherland M, Yu C, Walter R, Westendorf L, Valliere-Douglass J, et al.
Mol Cancer Ther
. 2017 Nov;
17(2):554-564.
PMID: 29142066
Treatment choices for acute myelogenous leukemia (AML) patients resistant to conventional chemotherapies are limited and novel therapeutic agents are needed. IL3 receptor alpha (IL3Rα, or CD123) is expressed on the...
5.
Li F, Ulrich M, Jonas M, Stone I, Linares G, Zhang X, et al.
Mol Cancer Ther
. 2017 Mar;
16(7):1347-1354.
PMID: 28341790
The primary mechanism of antibody-drug conjugates (ADC) is targeted delivery of a cytotoxic payload to tumor cells via cancer-associated membrane receptors. However, the tumor microenvironment likely plays a role in...
6.
Li F, Emmerton K, Jonas M, Zhang X, Miyamoto J, Setter J, et al.
Cancer Res
. 2016 Feb;
76(9):2710-9.
PMID: 26921341
Antibody-drug conjugates (ADC) comprise targeting antibodies armed with potent small-molecule payloads. ADCs demonstrate specific cell killing in clinic, but the basis of their antitumor activity is not fully understood. In...
7.
Lyon R, Bovee T, Doronina S, Burke P, Hunter J, Neff-LaFord H, et al.
Nat Biotechnol
. 2015 Jun;
33(7):733-5.
PMID: 26076429
The in vitro potency of antibody-drug conjugates (ADCs) increases with the drug-to-antibody ratio (DAR); however, ADC plasma clearance also increases with DAR, reducing exposure and in vivo efficacy. Here we...
8.
Sutherland M, Yu C, Lewis T, Miyamoto J, Morris-Tilden C, Jonas M, et al.
MAbs
. 2010 Jan;
1(5):481-90.
PMID: 20065652
Despite therapeutic advances, the long-term survival rates for acute myeloid leukemia (AML) are estimated to be 10% or less, pointing to the need for better treatment options. AML cells express...
9.
Garcia-Martinez L, Appleby M, Staehling-Hampton K, Andrews D, Chen Y, McEuen M, et al.
J Immunol
. 2004 Aug;
173(5):2995-3001.
PMID: 15322158
Using a mouse mutagenesis screen, we have identified CD83 as being critical for the development of CD4(+) T cells and for their function postactivation. CD11c(+) dendritic cells develop and function...
10.
Liu C, Takemasa A, Liles W, Goodman R, Jonas M, Rosen H, et al.
Blood
. 2002 Oct;
101(1):295-304.
PMID: 12393619
It is increasingly clear that there are caspase-dependent and -independent mechanisms for the execution of cell death and that the utilization of these mechanisms is stimulus- and cell type-dependent. Intriguingly,...